Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells

References

• Gallogly MM, Lazarus HM. Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med. 2016;7:73–83.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed Acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Am Soc Hematol Annu Meeting, Blood. 2015;126:6.
   Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016.[Epub ahead of print] PMID: 27895058.
   Google Scholar
• Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19:37–54.
   PubMed Web of Science ®Google Scholar
• Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol: off J Am Soc Clin Oncol. 2001;19:1485–1492.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin OQ, Graf P, et al. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol. 2008;48:763–775.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Ruetz S, Bodis S, et al. PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17–28.
   PubMedGoogle Scholar
• Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108:3477–3483.
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60.
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26:2061–2068.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol: off J Am Soc Clin Oncol. 2010;28:4339–4345.
   PubMed Web of Science ®Google Scholar
• Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015;15:428–32 e2.
   PubMed Web of Science ®Google Scholar
• Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90:276–281.
   PubMed Web of Science ®Google Scholar
• Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013;33:1341–1352.
   PubMed Web of Science ®Google Scholar
• Ramsingh G, Westervelt P, McBride A, et al. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol. 2014;99:272–278.
   PubMed Web of Science ®Google Scholar
• Dutreix C, Munarini F, Lorenzo S, et al. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol. 2013;72:1223–1234.
   PubMed Web of Science ®Google Scholar
• Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–1699.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38:693–710.
   PubMed Web of Science ®Google Scholar
• Del Corral A, Dutreix C, Huntsman-Labed A, et al. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemother Pharmacol. 2012;69:1255–1263.
   PubMed Web of Science ®Google Scholar
• Masson K, Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009;21:1717–1726.
   PubMed Web of Science ®Google Scholar
• Berenstein R. Class III receptor tyrosine kinases in acute leukemia - biological functions and modern laboratory analysis. Biomark Insights. 2015;10:1–14.
   PubMed Web of Science ®Google Scholar
• Annesley CE, Brown P. The biology and targeting of FLT3 in pediatric leukemia. Front Oncol. 2014;4:263.
   PubMedGoogle Scholar
• Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res off J Am Assoc Cancer Res. 2009;15:4263–4269.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Hovland R, Wergeland L, et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica. 2003;88:416–428.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Øyan AM, Kalland KH, et al. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Prolif. 2013;46:554–562.
   PubMed Web of Science ®Google Scholar
• Roberts R, Govender D. Gene of the month: KIT. J Clin Pathol. 2015;68:671–674.
   PubMed Web of Science ®Google Scholar
• Lennartsson J, Jelacic T, Linnekin D, et al. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23:16–43.
   PubMed Web of Science ®Google Scholar
• Edling CE, Hallberg B. C-Kit–a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39:1995–1998.
   PubMed Web of Science ®Google Scholar
• Stankov K, Popovic S, Mikov M. C-KIT signaling in cancer treatment. Curr Pharm Des. 2014;20:2849–2880.
   PubMed Web of Science ®Google Scholar
• Foss B, Mentzoni L, Bruserud Ø. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res. 2001;10:81–93.
   PubMedGoogle Scholar
• Padró T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875.
   PubMed Web of Science ®Google Scholar
• Saulle E, Riccioni R, Coppola S, et al. Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation. Br J Haematol. 2009;145:399–411.
   PubMed Web of Science ®Google Scholar
• Smith GA, Fearnley GW, Tomlinson DC, et al. The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis. Biosci Rep. 2015;35.pii: e00253.
   Web of Science ®Google Scholar
• Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A. 2001;98:10857–10862.
   PubMed Web of Science ®Google Scholar
• Foss B, Ulvestad E, Bruserud O. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol. 2001;67:267–278.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Gjertsen BT, Foss B, et al. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells–the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells. 2001;19:1–11.
   PubMed Web of Science ®Google Scholar
• Advani AS. Targeting the c-kit receptor in the treatment of acute myelogenous leukemia. Curr Hematol Malig Rep. 2006;1:101–107.
   PubMedGoogle Scholar
• Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2009;4:77–82.
   PubMedGoogle Scholar
• Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92:332–341.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol. 2013;5:a009100.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–1316.
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22:1276–1312.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Foss B, Ulvestad E, et al. Effects of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor. Platelets. 1998;9:352–358.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999;82:293–301.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 2013;122:1900–1913.
   PubMed Web of Science ®Google Scholar
• Willman CL, Stewart CC, Longacre TL, et al. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. Blood. 1991;77:726–734.
   PubMed Web of Science ®Google Scholar
• Notario V, Gutkind JS, Imaizumi M, et al. Expression of the fgr protooncogene product as a function of myelomonocytic cell maturation. J Cell Biol. 1989;109:3129–3136.
   PubMed Web of Science ®Google Scholar
• Link DC, Zutter M. The proto-oncogene c-fgr is expressed in normal mantle zone B lymphocytes and is developmentally regulated during myelomonocytic differentiation in vivo. Blood. 1995;85:472–479.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453–461.
   PubMed Web of Science ®Google Scholar
• Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol. 2004;172:5034–5040.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam H, Bruserud O. A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Front Immunol. 2016;7:205.
   PubMed Web of Science ®Google Scholar
• Cheng M, Huang K, Zhou J, et al. A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart. J Mol Cell Cardiol. 2015;81:49–53.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Nepstad I, Bruserud Ø, et al. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget. 2013;4:830–843.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118–1122.
   PubMed Web of Science ®Google Scholar
• Glenjen N, Hovland R, Wergeland L, et al. The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol. 2003;71:163–173.
   PubMed Web of Science ®Google Scholar
• Richine BM, Virts EL, Bowling JD, et al. Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia. Leukemia. 2016;2094–2097.
   PubMed Web of Science ®Google Scholar
• Sprissler C, Belenki D, Maurer H, et al. Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J. 2014;4:e240.
   PubMed Web of Science ®Google Scholar
• Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16:281–294.
   PubMed Web of Science ®Google Scholar
• Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014;25:226–242.
   PubMed Web of Science ®Google Scholar
• Boros K, Puissant A, Back M, et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget. 2015;6:25575–25587.
   PubMed Web of Science ®Google Scholar
• Shah CA, Bei L, Wang H, et al. Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells. Oncotarget. 2016. Oncotarget.10189. [Epub ahead of print].
   Web of Science ®Google Scholar
• Oellerich T, Oellerich MF, Engelke M, et al. Beta2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood. 2013;121:3889–399 S1–S66.
   PubMed Web of Science ®Google Scholar
• Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115:4497–4506.
   PubMed Web of Science ®Google Scholar
• Carnevale J, Ross L, Puissant A, et al. SYK regulates mTOR signaling in AML. Leukemia. 2013;27:2118–2128.
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20:2093–2101.
   PubMed Web of Science ®Google Scholar
• Ersvaer E, Kittang AO, Hampson P, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010;2:174–194.
   PubMed Web of Science ®Google Scholar
• Hampson P, Wang K, Ersvaer E, et al. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience. 2014;1:529–539.
   PubMedGoogle Scholar
• Hampson P, Wang K, Milverton L, et al. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis: Int J Program Cell Death. 2010;15:946–955.
   PubMed Web of Science ®Google Scholar
• Zabkiewicz J, Pearn L, Hills RK, et al. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica. 2014;99:858–864.
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Benanti JA. Create, activate, destroy, repeat: cdk1 controls proliferation by limiting transcription factor activity. Curr Genet. 2016;62:271–276.
   PubMed Web of Science ®Google Scholar
• Hedblom A, Laursen KB, Miftakhova R, et al. CDK1 interacts with RARgamma and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013;12:1251–1266.
   PubMed Web of Science ®Google Scholar
• Radomska HS, Alberich-Jorda M, Will B, et al. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest. 2012;122:2955–2966.
   PubMed Web of Science ®Google Scholar
• Tibes R, McDonagh KT, Lekakis L, et al. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Invest New Drugs. 2015;33:389–396.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005;106:2646–2654.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Nesthus I, Pawelec G. In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation. Cancer Chemother Pharmacol. 1995;37:70–78.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Lee S, Sikic BI, et al. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 1999;85:358–367.
   PubMed Web of Science ®Google Scholar
• Ganeshaguru K, Wickremasinghe RG, Jones DT, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002;87:167–176.
   PubMed Web of Science ®Google Scholar
• Hunter HM, Pallis M, Seedhouse CH, et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol. 2004;127:26–33.
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Fan D, Fidler IJ, et al. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol. 1997;53:245–247.
   PubMed Web of Science ®Google Scholar
• Utz I, Hofer S, Regenass U, et al. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer. 1994;57:104–110.
   PubMed Web of Science ®Google Scholar
• Erikstein BS, McCormack E, Tronstad KJ, et al. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leuk Res. 2010;34:77–84.
   PubMed Web of Science ®Google Scholar
• Yang X, Liu L, Sternberg D, et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005;65:7338–7347.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Austin S, Kishnani P. Phosphorylase kinase deficiency. In: Pagon RA, Adam MP, Ardinger HH, et al. editors. GeneReviews(R). Seattle (WA); 1993.
   Google Scholar
• Tvedt THA, Reikvam H, Aasebø E, et al. How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia? Expert Rev Qual Life Cancer Care. 2016;1:373–387.
   Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299.
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Stapnes C, et al. The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: the safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev. 2009;5:243–255.
   Google Scholar
• Fredly H, Gjertsen BT, Bruserud Ø. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics. 2013;5:12.
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Kittang AO, et al. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. 2013;5:13.
   PubMed Web of Science ®Google Scholar
• Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev. 2009;228:9–22.
   PubMed Web of Science ®Google Scholar
• Huang YC, Shieh HR, Chen YJ. Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells. Toxicol Vitro: Int J Published Assoc BIBRA. 2010;24:1705–1710.
   PubMed Web of Science ®Google Scholar
• Alkan SS, Rutschmann S, Grogg D, et al. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing. Cell Immunol. 1993;150:137–148.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move. J Exp Med. 2011;208:421–428.
   PubMed Web of Science ®Google Scholar
• Lyman SD, McKenna HJ. Flt3 ligand. In: Thompson AW, Lotze MT, editors. The Cytokine Handbook. 1. 4th edition. London-San Diego:Academic Press, Harcourt Brace & Co; 2003. p. 989–1010.
   Google Scholar
• Kvestad H, Evensen L, Lorens JB, et al. In vitro characterization of valproic acid, ATRA, and cytarabine used for disease-stabilization in human acute myeloid leukemia: antiproliferative effects of drugs on endothelial and osteoblastic cells and altered release of angioregulatory mediators by endothelial cells. Leuk Res Treatment. 2014;2014:143479.
   PubMedGoogle Scholar
• Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19:460–473.
   PubMed Web of Science ®Google Scholar
• Davis GE, Stratman AN, Sacharidou A, et al. Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol. 2011;288:101–165.
   PubMed Web of Science ®Google Scholar
• Haouas H. Angiogenesis and acute myeloid leukemia. Hematology. 2014;19:311–323.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Wu X, et al. KDR and Sema3 genes expression in bone marrow stromal cells and hematopoietic cells from leukemia patients and normal individuals. Hematology. 2005;10:307–312.
   PubMed Web of Science ®Google Scholar
• Poulos MG, Gars EJ, Gutkin MC, et al. Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Exp Hematol. 2014;42:976–986 e1–3.
   PubMed Web of Science ®Google Scholar
• Chang MY, Huang DY, Ho FM, et al. PKC-dependent human monocyte adhesion requires AMPK and Syk activation. PLoS One. 2012;7:e40999.
   PubMed Web of Science ®Google Scholar
• Vines CM, Potter JW, Xu Y, et al. Inhibition of beta 2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr. Immunity. 2001;15:507–519.
   PubMed Web of Science ®Google Scholar
• Kovács M, Németh T, Jakus Z, et al. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. J Exp Med. 2014;211:1993–2011.
   PubMed Web of Science ®Google Scholar
• Miller YI, Choi SH, Wiesner P, et al. The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL. Br J Pharmacol. 2012;167:990–999.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chen YH, Li LY, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011;13:87–94.
   PubMed Web of Science ®Google Scholar
• Warfel NA, Dolloff NG, Dicker DT, et al. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013;12:3689–3701.
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem. 2010;17:4448–4461.
   PubMed Web of Science ®Google Scholar
• He H, Zhao ZH, Han FS, et al. Overexpression of protein kinase C varepsilon improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction. Cell Death Dis. 2016;7:e2056.
   PubMed Web of Science ®Google Scholar
• Lee S, Cho HY, Bui HT, et al. The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta. BMC Cell Biol. 2014;15:42.
   PubMed Web of Science ®Google Scholar
• Haase H, Rink L. Signal transduction in monocytes: the role of zinc ions. Biometals: Int J Role Met Ions Biol, Biochem, Med. 2007;20:579–585.
   Web of Science ®Google Scholar
• Ding RQ, Tsao J, Chai H, et al. Therapeutic potential for protein kinase C inhibitor in vascular restenosis. J Cardiovasc Pharmacol Ther. 2011;16:160–167.
   PubMed Web of Science ®Google Scholar
• Drusbosky L, Gars E, Trujillo A, et al. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition. Leuk Res. 2015;39:984–989.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Brenner AK, Hagen KM, et al. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15:530–541.
   PubMed Web of Science ®Google Scholar
• Ito S, Barrett AJ, Dutra A, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2015;14:95–104.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Fredly H, et al. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw. 2012;23:140–153.
   PubMed Web of Science ®Google Scholar
• Kampen KR, Ter Elst A, de Bont ES. Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci: CMLS. 2013;70:1307–1317.
   PubMed Web of Science ®Google Scholar
• Möllgård L, Deneberg S, Nahi H, et al. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemother Pharmacol. 2008;62:439–448.
   PubMed Web of Science ®Google Scholar
• Hernandez-Valladares M, Aasebø E, Mjaavatten O, et al. Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biol Proced Online. 2016;18:13.
   PubMed Web of Science ®Google Scholar
• Aasebø E, Mjaavatten O, Vaudel M, et al. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. J Proteomics. 2016;145:214–225.
   PubMed Web of Science ®Google Scholar